1094 Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development
Guillaume Carmona, Omid Veiseh(Rice University), Rahul A. Sheth(Massachusetts General Hospital), Maria Jarvis(Rice University), Ryan Newman, Sudip Mukherjee(Indian Institute of Technology BHU), Samira Aghlara-Fotovat(Integrated BioTherapeutics (United States)), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Andrea Hernández(Rice University), Shirin Nouraein(Rice University), Peter Rios(TransUnion (United States)), Weiyi Peng(University of Houston), Andrew C. Hecht(Rice University), Jake Schladenhauffen, José Oberholzer(University Hospital of Zurich), Amanda Nash(Rice University)
Cited by 0
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
|Advanced Drug Delivery Reviews|2009|1.8k
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
|Clinical Cancer Research|2013|938
Size- and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates
|Nature Materials|2015|895
Electrospun chitosan-based nanofibers and their cellular compatibility
|Biomaterials|2005|888